{"PubmedArticle": [{"MedlineCitation": {"SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "OtherAbstract": [], "CitationSubset": ["IM"], "KeywordList": [], "GeneralNote": [], "PMID": "19944497", "DateCompleted": {"Year": "2010", "Month": "04", "Day": "29"}, "DateRevised": {"Year": "2022", "Month": "04", "Day": "09"}, "Article": {"ArticleDate": [{"Year": "2009", "Month": "11", "Day": "18"}], "Language": ["eng"], "ELocationID": ["10.1016/j.ejmech.2009.11.021"], "Journal": {"ISSN": "1768-3254", "JournalIssue": {"Volume": "45", "Issue": "2", "PubDate": {"Year": "2010", "Month": "Feb"}}, "Title": "European journal of medicinal chemistry", "ISOAbbreviation": "Eur J Med Chem"}, "ArticleTitle": "Novel quinolines and pyrimido[4,5-b]quinolines bearing biologically active sulfonamide moiety as a new class of antitumor agents.", "Pagination": {"StartPage": "738", "EndPage": "744", "MedlinePgn": "738-44"}, "Abstract": {"AbstractText": ["Some novel quinolines and pyrimido[4,5-b]quinolines have been synthesized. The structures of which were confirmed by elemental analyses and spectral data. All the target compounds were subjected to in-vitro antitumor activity against Ehrlich Ascites Carcinoma (EAC) cells. Compounds 24, 19 and 12 showed higher activity with IC(50) values (5.5, 6.9, 7 microg/ml) when compared with Doxorubicin as a reference drug (IC(50) value 38 microg/ml)."], "CopyrightInformation": "Copyright 2009 Elsevier Masson SAS. All rights reserved."}, "AuthorList": [{"AffiliationInfo": [{"Identifier": [], "Affiliation": "Medicinal, Aromatic and Poisonous Plants Research Center, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia."}], "Identifier": [], "LastName": "Alqasoumi", "ForeName": "Saleh I", "Initials": "SI"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Al-Taweel", "ForeName": "Areej M", "Initials": "AM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Alafeefy", "ForeName": "Ahmed M", "Initials": "AM"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Noaman", "ForeName": "Eman", "Initials": "E"}, {"AffiliationInfo": [], "Identifier": [], "LastName": "Ghorab", "ForeName": "Mostafa M", "Initials": "MM"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Eur J Med Chem", "NlmUniqueID": "0420510", "ISSNLinking": "0223-5234"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinolines"}, {"RegistryNumber": "0", "NameOfSubstance": "Sulfonamides"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["pathology"], "DescriptorName": "Carcinoma, Ehrlich Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Survival"}, {"QualifierName": [], "DescriptorName": "Drug Discovery"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Inhibitory Concentration 50"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Quinolines"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}, {"QualifierName": ["chemistry"], "DescriptorName": "Sulfonamides"}]}, "PubmedData": {"ReferenceList": [], "History": [{"Year": "2009", "Month": "6", "Day": "17"}, {"Year": "2009", "Month": "11", "Day": "4"}, {"Year": "2009", "Month": "11", "Day": "12"}, {"Year": "2009", "Month": "12", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2009", "Month": "12", "Day": "1", "Hour": "6", "Minute": "0"}, {"Year": "2010", "Month": "4", "Day": "30", "Hour": "6", "Minute": "0"}], "PublicationStatus": "ppublish", "ArticleIdList": ["19944497", "10.1016/j.ejmech.2009.11.021", "S0223-5234(09)00591-1"]}}], "PubmedBookArticle": []}